Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiEC grants orphan designation for Pharvaris' deucrictibant drug
DiJapan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD
FrBridgeBio's Beyonttra gains approval in Japan for ATTR-CM treatment
27.03.US FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumours
26.03.US FDA grants orphan drug status to Palatin's obesity treatment PL7737
25.03.NeuroNOS secures funding for autism treatment development
24.03.Duke-NUS and NUS Medicine launch centre for metabolomics research
21.03.FDA approves Novartis' Fabhalta for C3 glomerulopathy treatment
20.03.Porton Advanced and Eureka to expedite T-cell therapy development
19.03.Delpharm plans $140m investment to upgrade Boucherville facility in Canada
18.03.Health Canada approves Arcutis' roflumilast cream 0.15% for atopic dermatitis
17.03.FDA grants orphan drug status for Korro Bio's AATD therapy
14.03.FDA clears PDS Biotechnology's Versamune MUC1 combo for mCRC
13.03.LGM Pharma to expand manufacturing capabilities with $6m investment
12.03.Aprea and MD Anderson sign agreement for APR-1051
11.03.Vivus' Qsymia gains market approval in UAE for obesity treatment
10.03.UK MHRA approves Vertex's Alyftrek for cystic fibrosis
07.03.Relief Therapeutics and Renexxion terminate merger talks
06.03.CordenPharma announces $1bn investment in peptide development and production
05.03.FairJourney acquires Charles River's San Francisco site
04.03.FDA approves Celltrion's biosimilars for various indications
03.03.EMA's CHMP recommends marketing authorisation for Novartis' Fabhalta
28.02.FDA grants fast track status for Avobis' AVB-114
27.02.China's NMPA approves Fosun's NDA of Tenapanor Hydrochloride tablets
26.02.Health Canada grants marketing authorisation to Kashiv's Pegfilgrastim